PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › HS-10506

Drugs in development · updated 30 October 2026

HS-10506: clinical trials and development status

Development codeNot approved in the USNo EMA authorisationEstimated launch Aug 2029 – Jun 2030 (Phuturdex estimate)

As of 30 October 2026 HS-10506 is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 2 diseases. The most advanced phase is III.

4Active trials
IIIMost advanced phase
2Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow HS-10506 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Sleep Initiation and Maintenance DisordersIII2NCT07677384
Follicular lymphomaI1NCT07844967

Everything on HS-10506

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch